• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

第一代抗肥胖药物。

First-Generation Anti-Obesity Medications.

作者信息

Barenbaum Sarah R, Aras Mohini

机构信息

Comprehensive Weight Control Center and Division of Endocrinology, Diabetes & Metabolism, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY.

出版信息

Diabetes Spectr. 2024 Nov 15;37(4):296-302. doi: 10.2337/dsi24-0003. eCollection 2024 Fall.

DOI:10.2337/dsi24-0003
PMID:39649696
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11623038/
Abstract

The development of second-generation anti-obesity medications (AOMs) has transformed the treatment of obesity. However, the first-generation AOMs are still essential tools in the treatment of obesity. The decision of which AOM to initiate must be individualized taking into account patient preference, safety, tolerability, cost, and supply.

摘要

第二代抗肥胖药物（AOMs）的发展改变了肥胖症的治疗方式。然而，第一代AOMs仍然是肥胖症治疗中的重要工具。决定启动哪种AOM必须因人而异，要考虑患者的偏好、安全性、耐受性、成本和供应情况。

相似文献

1
First-Generation Anti-Obesity Medications.第一代抗肥胖药物。
Diabetes Spectr. 2024 Nov 15;37(4):296-302. doi: 10.2337/dsi24-0003. eCollection 2024 Fall.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方：益处与风险
3
Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.基于 FDA 不良事件报告系统数据库的真实世界研究：抗肥胖药物与消化道不良事件关联性的分层分析。
BMC Pharmacol Toxicol. 2024 Sep 12;25(1):64. doi: 10.1186/s40360-024-00789-9.
4
Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications.抗肥胖药物治疗停药后体重的变化轨迹。
BMC Med. 2025 Jul 22;23(1):398. doi: 10.1186/s12916-025-04200-0.
5
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理（2025年结石病专家共识）
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
6
Efficacy of Antiobesity Medications in Patients With Celiac Disease on a Gluten-free Diet: A Retrospective Matched Cohort Study.基于无麸质饮食的乳糜泻患者使用抗肥胖药物的疗效：一项回顾性匹配队列研究。
J Clin Gastroenterol. 2024 Aug 1;58(7):650-655. doi: 10.1097/MCG.0000000000001931.
7
Perceptions of anti-obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study.美国肥胖人群和医疗服务提供者对抗肥胖药物的认知：OBSERVE研究结果
Obesity (Silver Spring). 2025 Jun;33(6):1076-1086. doi: 10.1002/oby.24290. Epub 2025 Apr 24.
8
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
9
Advancements and challenges in the management of obesity using pharmacotherapy (Review).药物治疗肥胖症管理的进展与挑战（综述）
Exp Ther Med. 2025 Jun 25;30(2):162. doi: 10.3892/etm.2025.12912. eCollection 2025 Aug.
10
Anterior Approach Total Ankle Arthroplasty with Patient-Specific Cut Guides.使用患者特异性截骨导向器的前路全踝关节置换术。
JBJS Essent Surg Tech. 2025 Aug 15;15(3). doi: 10.2106/JBJS.ST.23.00027. eCollection 2025 Jul-Sep.

本文引用的文献

1
New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications.新视野。用第二代肥胖症药物靶向治疗的新模式。
J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1339-e1347. doi: 10.1210/clinem/dgab848.
2
A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa.一项针对暴食症和神经性贪食症患者的苯丁胺/托吡酯 ER 的随机、安慰剂对照交叉试验。
Int J Eat Disord. 2020 Feb;53(2):266-277. doi: 10.1002/eat.23192. Epub 2019 Nov 13.
3
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.利拉鲁肽治疗 3 年对糖尿病前期个体的 2 型糖尿病风险降低和体重管理的效果：一项随机、双盲试验。
Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23.
4
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
5
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.美国临床内分泌医师协会和美国内分泌学会肥胖患者医疗护理综合临床实践指南
Endocr Pract. 2016 Jul;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL. Epub 2016 May 24.
6
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.利拉鲁肽治疗 2 型糖尿病患者的体重减轻疗效：SCALE 糖尿病随机临床试验。
JAMA. 2015 Aug 18;314(7):687-99. doi: 10.1001/jama.2015.9676.
7
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.利拉鲁肽 3.0 毫克在体重管理中的随机、对照试验。
N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892.
8
Pharmacological management of obesity: an endocrine Society clinical practice guideline.肥胖的药物治疗：内分泌学会临床实践指南
J Clin Endocrinol Metab. 2015 Feb;100(2):342-62. doi: 10.1210/jc.2014-3415. Epub 2015 Jan 15.
9
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.2 型糖尿病的减肥治疗：苯丁胺和托吡酯缓释的效果。
Diabetes Care. 2014 Dec;37(12):3309-16. doi: 10.2337/dc14-0930. Epub 2014 Sep 23.
10
Weight loss strategies for treatment of obesity.肥胖治疗的体重减轻策略。
Prog Cardiovasc Dis. 2014 Jan-Feb;56(4):465-72. doi: 10.1016/j.pcad.2013.09.005. Epub 2013 Oct 11.